{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T21:09:47Z","timestamp":1790888987962,"version":"4.1.0"},"reference-count":25,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2024,12,23]],"date-time":"2024-12-23T00:00:00Z","timestamp":1734912000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/501100004735","name":"Natural Science Foundation of Hunan Province","doi-asserted-by":"publisher","award":["2021JJ40886"],"award-info":[{"award-number":["2021JJ40886"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Hunan Provincial Health Commission","award":["B202303046886"],"award-info":[{"award-number":["B202303046886"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,1,20]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Chronic myeloid leukemia (CML) is a malignant hyperplastic tumor that originates from pluripotent hematopoietic stem cells in the bone marrow. The introduction of tyrosine kinase inhibitors has significantly improved the survival rates of CML patients. This study aimed to identify immune-related genes associated with the response to imatinib (IM) therapy in CML. Gene expression profiles from IM-treated CML patients were obtained from the Gene Expression Omnibus database and categorized into high- and low-score groups based on immune scores calculated using the ESTIMATE algorithm. Subsequent bioinformatics analysis identified 428 differentially expressed immune-related genes in the CML context. Functional enrichment analysis revealed that these genes were involved in immune-related pathways, including T-cell receptor signaling and cytokine\u2013cytokine receptor interaction. Finally, based on five modules in weighted gene co-expression network analysis and the top-ranked degree, 10 hub genes were identified. Receiver operating characteristic analysis in two Gene Expression Omnibus datasets identified IL10RA, SCN9A, and SLC26A11 as potential biomarkers for predicting IM response. We further validated these biomarkers in an independent clinical cohort of 60 CML patients treated with IM. Results from quantitative real-time polymerase chain reaction (qRT-PCR) revealed high expression of IL10RA and SLC26A11 in responders, while SCN9A showed low expression. All three genes had an area under the curve greater than 0.75, confirming their potential as predictive biomarkers. These findings deepen our understanding of functional characteristics and immune-related molecular mechanisms underlying IM response and offer promising predictive biomarkers.<\/jats:p>","DOI":"10.1093\/carcin\/bgae080","type":"journal-article","created":{"date-parts":[[2024,12,23]],"date-time":"2024-12-23T13:12:42Z","timestamp":1734959562000},"source":"Crossref","is-referenced-by-count":2,"title":["Immune-related genes for the prediction of response to imatinib therapy in chronic myeloid leukemia"],"prefix":"10.1093","volume":"46","author":[{"given":"Pu","family":"Yang","sequence":"first","affiliation":[{"name":"Department of Neurology, The Third Xiangya Hospital of Central South University ,\u00a0 No.\u00a0138 Tongzipo Road, Changsha, Hunan 410013 ,","place":["People\u2019s Republic of China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4437-6029","authenticated-orcid":false,"given":"Qian","family":"Yu","sequence":"additional","affiliation":[{"name":"Division of Hematology, Second Xiangya Hospital, Central South University , No. 139th Renmin Middle Road, Changsha, Hunan 410011 ,","place":["People\u2019s Republic of China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,12,23]]},"reference":[{"key":"2025022113273506400_CIT0001","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1056\/NEJM199909023411016","article-title":"Chronic myeloid leukemia","volume":"341","author":"Nash","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"2025022113273506400_CIT0002","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1126\/science.2408149","article-title":"Tyrosine kinase activity and transformation potency of bcr-abl oncogene products","volume":"247","author":"Lugo","year":"1990","journal-title":"Science (New York, NY)."},{"key":"2025022113273506400_CIT0003","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1182\/blood-2012-03-380147","article-title":"How I treat CML blast crisis","volume":"120","author":"Hehlmann","year":"2012","journal-title":"Blood"},{"key":"2025022113273506400_CIT0004","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","article-title":"Oncology meets immunology: the cancer-immunity cycle","volume":"39","author":"Chen","year":"2013","journal-title":"Immunity"},{"key":"2025022113273506400_CIT0005","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1126\/science.aar4060","article-title":"Cancer immunotherapy using checkpoint blockade","volume":"359","author":"Ribas","year":"2018","journal-title":"Science (New York, NY)."},{"key":"2025022113273506400_CIT0006","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1038\/leu.2012.313","article-title":"Re-emergence of interferon-\u03b1 in the treatment of chronic myeloid leukemia","volume":"27","author":"Talpaz","year":"2013","journal-title":"Leukemia"},{"key":"2025022113273506400_CIT0007","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.1182\/bloodadvances.2019000195","article-title":"Gene expression signature that predicts early molecular response failure in chronic-phase CML patients on frontline imatinib","volume":"3","author":"Kok","year":"2019","journal-title":"Blood Adv."},{"key":"2025022113273506400_CIT0008","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1002\/cncr.25527","article-title":"Monitoring molecular response in chronic myeloid leukemia","volume":"117","author":"Cortes","year":"2011","journal-title":"Cancer"},{"key":"2025022113273506400_CIT0009","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1182\/blood-2009-03-210732","article-title":"A gene expression signature of CD34+ cells to predict major cytogenetic response in chronic-phase chronic myeloid leukemia patients treated with imatinib","volume":"115","author":"McWeeney","year":"2010","journal-title":"Blood"},{"key":"2025022113273506400_CIT0010","doi-asserted-by":"publisher","first-page":"2150","DOI":"10.1038\/s41375-023-02048-y","article-title":"European LeukemiaNet laboratory recommendations for the diagnosis and management of chronic myeloid leukemia","volume":"37","author":"Cross","year":"2023","journal-title":"Leukemia"},{"key":"2025022113273506400_CIT0011","doi-asserted-by":"publisher","first-page":"e204","DOI":"10.1093\/nar\/gkq871","article-title":"Optimizing the noise versus bias trade-off for Illumina whole genome expression BeadChips","volume":"38","author":"Shi","year":"2010","journal-title":"Nucleic Acids Res."},{"key":"2025022113273506400_CIT0012","doi-asserted-by":"publisher","first-page":"2612","DOI":"10.1038\/ncomms3612","article-title":"Inferring tumour purity and stromal and immune cell admixture from expression data","volume":"4","author":"Yoshihara","year":"2013","journal-title":"Nat. Commun."},{"key":"2025022113273506400_CIT0013","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.1093\/nar\/gkv007","article-title":"limma powers differential expression analyses for RNA-sequencing and microarray studies","volume":"43","author":"Ritchie","year":"2015","journal-title":"Nucleic Acids Res."},{"key":"2025022113273506400_CIT0014","doi-asserted-by":"publisher","first-page":"R80","DOI":"10.1186\/gb-2004-5-10-r80","article-title":"Bioconductor: open software development for computational biology and bioinformatics","volume":"5","author":"Gentleman","year":"2004","journal-title":"Genome Biol."},{"key":"2025022113273506400_CIT0015","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1089\/omi.2011.0118","article-title":"clusterProfiler: an R package for comparing biological themes among gene clusters","volume":"16","author":"Yu","year":"2012","journal-title":"OMICS J. Integr. Biol."},{"key":"2025022113273506400_CIT0016","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1186\/1471-2105-9-559","article-title":"WGCNA: an R package for weighted correlation network analysis","volume":"9","author":"Langfelder","year":"2008","journal-title":"BMC Bioinf."},{"key":"2025022113273506400_CIT0017","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1016\/j.ccell.2020.03.006","article-title":"Response and resistance to BCR-ABL1-targeted therapies","volume":"37","author":"Braun","year":"2020","journal-title":"Cancer Cell."},{"key":"2025022113273506400_CIT0018","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1056\/NEJMoa011573","article-title":"Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia","volume":"346","author":"Kantarjian","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"2025022113273506400_CIT0019","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1126\/scitranslmed.3009073","article-title":"A therapeutically targetable mechanism of BCR-ABL-independent imatinib resistance in chronic myeloid leukemia","volume":"6","author":"Ma","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"2025022113273506400_CIT0020","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1038\/s41375-020-0732-1","article-title":"SRSF1 mediates cytokine-induced impaired imatinib sensitivity in chronic myeloid leukemia","volume":"34","author":"Sinnakannu","year":"2020","journal-title":"Leukemia"},{"key":"2025022113273506400_CIT0021","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1111\/j.1349-7006.2009.01172.x","article-title":"Haploinsufficiency and acquired loss of Bcl11b and H2AX induces blast crisis of chronic myelogenous leukemia in a transgenic mouse model","volume":"100","author":"Nagamachi","year":"2009","journal-title":"Cancer Sci."},{"key":"2025022113273506400_CIT0022","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1182\/blood-2005-05-2155","article-title":"Molecular profiling of CD34+ cells identifies low expression of CD7, along with high expression of proteinase 3 or elastase, as predictors of longer survival in patients with CML","volume":"107","author":"Yong","year":"2006","journal-title":"Blood"},{"key":"2025022113273506400_CIT0023","doi-asserted-by":"publisher","first-page":"835563","DOI":"10.3389\/fonc.2022.835563","article-title":"Pro-Inflammatory and pro-oxidative changes during nilotinib treatment in cml patients: results of a prospective multicenter front-line TKIs Study (KIARO Study)","volume":"12","author":"Sicuranza","year":"2022","journal-title":"Front. Oncol."},{"key":"2025022113273506400_CIT0024","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1002\/ijc.25113","article-title":"Anti-inflammatory M2 type macrophages characterize metastasized and tyrosine kinase inhibitor-treated gastrointestinal stromal tumors","volume":"127","author":"van Dongen","year":"2010","journal-title":"Int. J. Cancer"},{"key":"2025022113273506400_CIT0025","doi-asserted-by":"publisher","first-page":"E001","DOI":"10.3760\/cma.j.issn.0253-2727.2020.05.E001","article-title":"The guidelines for diagnosis and treatment of chronic myelogenous leukemia in China (2020 edition)","volume":"41","author":"Chinese Society of Hematology CMA","year":"2020","journal-title":"Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi."}],"container-title":["Carcinogenesis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/carcin\/advance-article-pdf\/doi\/10.1093\/carcin\/bgae080\/61265924\/bgae080.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/carcin\/article-pdf\/46\/1\/bgae080\/61265924\/bgae080.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/carcin\/article-pdf\/46\/1\/bgae080\/61265924\/bgae080.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T13:27:50Z","timestamp":1740144470000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/carcin\/article\/doi\/10.1093\/carcin\/bgae080\/7931447"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,23]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1,20]]}},"URL":"https:\/\/doi.org\/10.1093\/carcin\/bgae080","relation":{},"ISSN":["0143-3334","1460-2180"],"issn-type":[{"value":"0143-3334","type":"print"},{"value":"1460-2180","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,1]]},"published":{"date-parts":[[2024,12,23]]},"article-number":"bgae080"}}